Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Nicergoline

Plain-language summaryIntrigue 40 / 100

Nicergoline (Sermion) is a semisynthetic ergoline developed at Farmitalia in Italy and approved across Europe for cerebrovascular disease and age-related cognitive decline. It blocks alpha-1 adrenergic receptors (causing cerebral vessel dilation), inhibits platelet aggregation, and has weak cholinergic effects. Some studies suggested mild improvements in memory and behavior in dementia patients, but the evidence base is heavily Eastern European and methodologically uneven. It is no longer marketed in the US and is rarely used in modern Western practice. Survives in nootropic communities and in markets that approved it long ago. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

A decades-old European-approved ergoline cerebrovascular agent with genuine but dated multi-target activity and thin modern replication

Nicergoline is a semisynthetic ergoline derivative that’s been on European pharmacy shelves since the 1970s under the name Sermion, indicated for cerebrovascular insufficiency and age-related cognitive decline. That lineage tells you most of what you need to know about where it sits in the 2025 research conversation: it’s a mature compound with a real but dated evidence base, occupying a corner of the literature that doesn’t see a lot of fresh traffic.

The mechanism has some genuine layers worth acknowledging. Alpha-1 adrenergic antagonism in cerebral vasculature is the headline, but nicergoline also inhibits platelet aggregation, shows weak nicotinic and muscarinic activity, and has been reported to modulate acetylcholinesterase activity in several preclinical models. Thats a multi-target profile, and we don’t want to dismiss it entirely. The problem is that none of those mechanisms are novel in the current research climate. Alpha-1 antagonism for cerebrovascular dilation is thoroughly trodden ground; AChE modulation is the mechanism half the cholinergic literature has already exhausted; platelet inhibition is standard for anything touching vascular biology. Stacking them in one molecule is interesting historically but doesn’t create meaningful new pharmacology by today’s standards.

The evidence base is real. European approval means clinical trials were run and regulators signed off, and there are systematic reviews and meta-analyses in the cognitive decline space suggesting modest improvements in neuropsychological outcomes in patients with cerebrovascular disease. But here’s the thing: by modern trial design standards, the pivotal evidence is unimpressive. Many core studies are old, small-N, and built around diagnostic categories like cerebrovascular insufficiency and mild cognitive impairment that have been substantially revised since. Independent replication using current methodology is thin.

Differentiation is the core problem. If you’re working on cerebrovascular biology, there are more specific probes. If you’re targeting alpha-1 adrenergic systems in the CNS, there are cleaner tools. If you’re chasing AChE biology, the cholinesterase inhibitor literature is far richer and more current. Nicergoline doesn’t define its category or dominate on any single dimension. Its value is narrowly as a reference ergoline cerebrovascular agent for investigators building on the specific European literature of that pharmacological class, and that’s a limited research mandate.

We’d prioritize nicergoline only for programs that specifically need a comparator within the ergoline cerebrovascular space or are revisiting historical mechanistic claims with modern methodology. For anyone else, the opportunity cost is high relative to what adjacent mechanistic territory can offer.

Novelty

22

Mechanism promise

35

In-category differentiation

30

Evidence quality

48

Translational signal

45

Research bench value

35

Rationale Nicergoline is a mature, EU-approved compound with a real multi-target mechanism (alpha-1 antagonism, AChE modulation, platelet inhibition), but novelty is negligible by 2025 standards, differentiation against cleaner probes in each mechanistic category is weak, and the clinical evidence base is old and low-powered by modern RCT criteria. Scores land in the piracetam tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Ergoline derivative / alpha-1 antagonist + cerebrovascular agent

A semisynthetic ergoline derivative; an alpha-1 adrenergic antagonist with cerebrovascular and acetylcholinesterase modulatory activity.

Abstract

Nicergoline (10-alpha-methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate; CAS 27848-84-6; molecular formula C24H26BrN3O3; molecular weight 484.39) is a semisynthetic ergoline developed at Farmitalia (Italy) and approved in several European countries under the trade name Sermion for cerebrovascular disease and age-related cognitive decline. Mechanism: alpha-1 adrenergic antagonism (cerebrovascular dilation), inhibition of platelet aggregation, weak nicotinic and muscarinic effects, and modulation of acetylcholinesterase activity in some studies. Plasma half-life is approximately 2 hours for the parent compound; the active metabolite 1,6-dimethyl-8-beta-hydroxymethyl-10-alpha-methoxy-ergoline (MMDL) has substantially longer half-life. Approved for cerebrovascular insufficiency in Europe; not approved in the US. Used as a reference ergoline cerebrovascular agent in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-308Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
D-Serine

Plain-language summaryIntrigue 68 / 100

D-serine is the mirror-image form of the amino acid serine, and your brain makes it on purpose. It is the obligate co-agonist at the synaptic NMDA receptor, meaning the receptor will not open without it sitting in a dedicated pocket alongside glutamate. An enzyme called serine racemase builds it; another called DAAO breaks it down. Researchers have tested giving it as a drug to boost NMDA function in schizophrenia (where reduced NMDA signaling is implicated in negative and cognitive symptoms) and in depression. Phase 2 trials show small but real effects. The competing strategy is to inhibit DAAO so the brain keeps more of its own. The canonical NMDA glycine-site co-agonist for neuroscience research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

48/100

Canonical endogenous NMDA co-agonist; indispensable synaptic probe with modest clinical signal in schizophrenia

Yeah, D-serine isn’t a discovery compound or a clinical moonshot. It’s the obligatory co-agonist at synaptic NMDA receptors that your brain makes itself, and has been studied intensively since the late 1990s when Wolosker, Snyder and colleagues pinned serine racemase as the biosynthetic enzyme. On novelty, we’re not pretending this is fresh territory.

Here’s the thing: what makes D-serine interesting in 2026 isn’t novelty, it’s bench utility. If you’re running any NMDA receptor biology — LTP assays, synaptic plasticity models, glutamate hypothesis schizophrenia work — D-serine is the compound you reach for to saturate the glycine site at synaptic NMDARs. And that matters because D-serine and glycine are not interchangeable here: D-serine is the preferred endogenous co-agonist at synaptic NMDARs in cortex and hippocampus, while glycine hits extrasynaptic receptors preferentially. Use glycine where you should use D-serine, and you’re probing a different receptor population. That distinction is load-bearing in any serious NMDA-focused program.

The mechanism is genuinely elegant. Serine racemase converts L-serine to D-serine; D-amino acid oxidase (DAAO) degrades it. That serine racemase/DAAO regulatory axis is itself a research target — DAAO inhibitors like sodium benzoate and luvadaxistat (TAK-831) were developed precisely because they elevate endogenous D-serine levels without flooding the system with exogenous amino acid. The endogenous level story powers the schizophrenia hypothesis: reduced NMDA receptor function from insufficient D-serine availability is one of the more coherent mechanistic accounts of negative symptoms and cognitive deficits in that population.

On clinical evidence, the phase 2 trials exist. Heresco-Levy’s group and several others have run them. Effects on negative symptoms and cognitive function are real but modest — consistent direction, meaningful p-values in several trials, but not effect sizes that would get anyone excited at a clinical development meeting. It hasnt gone to phase 3. The DAAO inhibitor path is the more active clinical development vector right now, which makes exogenous D-serine administration somewhat less central as a therapeutic candidate and somewhat more of a reference tool.

What we like is the bench probe value. Any lab interrogating NMDA co-agonism, glycine-site pharmacology, or the serine racemase/DAAO axis needs D-serine in the toolkit. Sourcing is clean — high-purity free amino acid from major chemical suppliers, straightforward aqueous reconstitution, no solubility headaches. What we dont love is the clinical stall. A compound this tightly coupled to NMDA synaptic biology should anchor research programs, and it does — just not as a frontier target. It anchors them as the reference standard against which everything more novel gets measured.

Novelty

28

Mechanism promise

55

In-category differentiation

55

Evidence quality

52

Translational signal

42

Research bench value

65

Rationale D-serine’s D-stereoisomeric identity and specific serine racemase/DAAO biosynthetic axis distinguish it from generic L-serine or plain amino acids, so the basic-aa cap does not apply; scores are dragged down by low novelty (mature 1990s-2000s literature) and a stalled clinical development arc, but bench-value is meaningfully elevated as the canonical synaptic NMDA co-agonist that cannot simply be substituted with glycine in properly-designed NMDAR studies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous NMDA receptor co-agonist

D-stereoisomer of serine; an endogenous obligatory co-agonist at the NMDA receptor glycine site.

Abstract

D-serine ((R)-2-amino-3-hydroxypropanoic acid; CAS 312-84-5; molecular formula C3H7NO3; molecular weight 105.09) is the D-stereoisomer of serine, an endogenous obligatory co-agonist at the glycine site of NMDA receptors. The compound is biosynthesized in the brain by serine racemase (the enzyme that converts L-serine to D-serine) and is metabolized by D-amino acid oxidase (DAAO). D-serine is the principal endogenous co-agonist for synaptic NMDA receptors in the cortex and hippocampus, while glycine itself co-agonizes extrasynaptic NMDA receptors. Pharmacologically, exogenous D-serine elevates NMDA receptor function, with research interest in schizophrenia (where reduced NMDA function is hypothesized as a contributor to negative symptoms and cognitive deficits) and depression (NMDA modulation as antidepressant target). Phase 2 trials in schizophrenia have shown small effects. Plasma half-life is approximately 4 hours; oral bioavailability is moderate. The DAAO inhibitor approach is an alternative to direct D-serine administration. Used as the canonical NMDA glycine-site co-agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-374Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Stanozolol

Plain-language summaryIntrigue 48 / 100

Stanozolol (Winstrol) is a 17-alpha-alkylated synthetic anabolic steroid developed by Sterling-Winthrop in 1962, distinguished by a pyrazole ring fused to the steroid A-ring. The fusion shifts the anabolic-to-androgenic ratio higher than testosterone and supports oral activity. FDA-approved historically for hereditary angioedema (largely replaced now by C1-inhibitor and icatibant) and a few other niche uses. Its place in popular memory belongs to Ben Johnson, whose 1988 Seoul Olympic 100m gold medal was stripped after a positive stanozolol test. Hepatotoxicity is the main limiting concern, the standard cost of 17-alpha-alkylation. Schedule III. Used in research as a reference oral AAS. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

37/100

A historically significant reference AAS with mature mechanism and declining research relevance

Look, stanozolol is not a mystery. It’s been around since 1962, it made Ben Johnson the most famous disqualified sprinter in history, and the mechanism is what you’d expect: androgen receptor agonism via a pyrazol-fused 17-alpha-alkylated backbone that shifts the anabolic-to-androgenic ratio favorably relative to testosterone. Sterling-Winthrop knew what they were doing structurally. But knowing what something does and finding it interesting in 2026 are different things.

The mechanism story starts and ends with AR binding. The pyrazole fusion at the A-ring is chemically clever for its era, and the oral bioavailability is real. What isn’t real anymore is the clinical urgency. The hereditary angioedema indication that got Winstrol its FDA approval has been largely displaced by C1-inhibitor concentrates and icatibant. Those agents are cleaner, better-tolerated, and don’t carry the hepatotoxicity liability that 17-alpha-alkylated steroids all share to varying degrees. The indication that justified the compound’s existence in the clinic is essentially a historical artifact at this point.

What we’re left with is a Schedule III reference compound. That’s not nothing. If you’re running AAS pharmacology studies, SHBG displacement work, or comparative androgen receptor affinity panels, stanozolol occupies a specific and well-characterized position in the reference set. The literature is extensive enough that you can contextualize your findings against a real body of evidence. That’s the bench value argument, and it’s legitimate but limited. Newer AAS analogs with more interesting selectivity profiles have appeared in the literature if your goal is genuinely advancing the mechanistic frontier.

The evidence quality is actually respectable for what it is. FDA approval, multi-decade use, clear pharmacokinetics, well-characterized toxicity. But high evidence quality on a mature well-understood compound is almost a negative signal for research interest. It means the question has already been answered. There’s no ambiguity left to resolve with stanozolol that hasn’t already been resolved, which is why the novelty score sits at the floor and drags the overall down hard.

Honestly, if you’re building a research program around androgen biology in 2026, the interesting questions are in selective androgen receptor modulators, tissue-selective AAS fragments, or non-steroidal AR modulators. Stanozolol tells you where that field came from, not where it’s going. We think it earns its place in the library as a reference compound, but we’d be doing investigators a disservice if we scored it as if it were an active frontier.

Novelty

18

Mechanism promise

22

In-category differentiation

35

Evidence quality

60

Translational signal

55

Research bench value

48

Rationale Stanozolol scores low on novelty and mechanism because it’s a 1962 oral AAS with well-understood AR agonism and an indication space that modern therapy has largely superseded; evidence quality and translational signal are genuine given FDA approval and decades of clinical use, but those points are offset by near-zero novelty and limited differentiation from a saturated class. Schedule III cap (75) does not bind; the raw weighted score of 37 reflects the compound’s historical-reference-only status.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

17-alpha-alkylated heterocyclic AAS

A pyrazol-fused 17-alpha-alkylated AAS; the steroid involved in the Ben Johnson 1988 Olympic doping case; clinically used historically for hereditary angioedema.

Abstract

Stanozolol (17-beta-hydroxy-17-alpha-methyl-5-alpha-androstano[3,2-c]pyrazole; CAS 10418-03-8; molecular formula C21H32N2O; molecular weight 328.49) is a pyrazol-fused 17-alpha-alkylated synthetic AAS developed by Sterling-Winthrop in 1962 and approved by the FDA (Winstrol) for hereditary angioedema and other indications. The pyrazole fusion at the A-ring increases the anabolic-to-androgenic ratio relative to testosterone and supports oral activity. Plasma half-life is approximately 9 hours (oral). Schedule III. The compound’s place in popular culture is dominated by the Ben Johnson case at the 1988 Seoul Olympics, where his 100m gold medal was stripped after positive testing for stanozolol. The clinical use in hereditary angioedema (rare, often replaced by C1-INH or icatibant in modern practice) demonstrates the compound’s effect on hepatic protein synthesis. Hepatotoxicity is the principal limitation. Used as a reference oral AAS in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-390Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tacrine

Plain-language summaryIntrigue 48 / 100

Tacrine, sold as Cognex, was the first FDA-approved Alzheimer disease medication (1993). It is rarely prescribed today owing to hepatotoxicity, but remains a research reference compound for cholinesterase inhibition. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

31/100

Historically foundational AChE inhibitor, clinically obsolete, retained only as a pharmacological probe and hybrid-molecule scaffold

Look, tacrine holds a specific place in pharmacological history. It was the compound that proved cholinesterase inhibition could work in Alzheimer disease. That was 1993. The question in 2026 is what it offers a researcher today, and the honest answer is: narrow but real probe utility, not much else.

The mechanism story is more interesting than people give it credit for. Tacrine isn’t a clean AChE inhibitor the way donepezil is; the aminoacridine scaffold also hits BChE and picks up weak NMDA receptor antagonism and modest sodium channel blockade. For researchers studying multi-target directed ligands (MTDL) in the AD space, that profile matters. Tacrine hybrids with memantine, with galantamine, with various natural product fragments have been a minor but productive research thread going back to the early 2000s. The scaffold is a legitimate template for MTDL design, and thats where we think the contemporary bench value actually lives.

What we don’t like is everything else about it as a primary research target. The hepatotoxicity is dose-related and reversible on discontinuation in most cases, yes, but it means roughly half of patients in the original trials developed clinically significant ALT elevation requiring monitoring or drug discontinuation. That’s not a side-effect profile anyone is trying to rehabilitate for clinical use when donepezil, rivastigmine, and galantamine all exist. The translational signal, real and FDA-validated, is essentially historical now. Nobody is running a new tacrine arm in a clinical study in 2026.

Evidence quality is genuinely solid in one narrow sense: this compound cleared FDA approval with multiple phase 3 trials, establishing a regulatory and clinical record that most research compounds never approach. But the evidence is old, effect sizes were modest by modern standards, and the safety signal ultimately drove market withdrawal in 2013 after declining prescriptions made the compound commercially unviable. We score evidence at 65 here, crediting the actual clinical program, not the contemporary relevance of the data.

Novelty is essentially zero. The mechanism is mature, the compound is decades old, the literature is not growing in any meaningful direction. Differentiation gets punished hard because better-tolerated AChE inhibitors have replaced tacrine everywhere that matters, except in enzyme kinetics assays and hybrid-molecule research where it functions as a reference standard.

Honestly, if your research program is in cholinesterase pharmacology or MTDL design for neurodegeneration, tacrine is a legitimate template and a useful comparator. That’s real. But it’s not a compound a serious investigator would prioritize as a primary target right now, and scoring it higher than that would misrepresent what the library is for.

Novelty

10

Mechanism promise

22

In-category differentiation

18

Evidence quality

65

Translational signal

40

Research bench value

52

Rationale Tacrine’s score is dragged down by near-zero novelty and clear clinical obsolescence driven by hepatotoxicity; surviving research value is narrow, living in its role as a reference compound and MTDL scaffold rather than as a therapeutic lead worth pursuing.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Aminoacridine acetylcholinesterase inhibitor

The first FDA-approved Alzheimer disease therapy (1993), withdrawn for hepatotoxicity but historically important and retained as a research probe.

Abstract

Tacrine (Cognex, 1,2,3,4-tetrahydroacridin-9-amine; CAS 321-64-2; molecular formula C13H14N2; molecular weight 198.27) is the first FDA-approved cholinesterase inhibitor for Alzheimer disease, granted approval in 1993 and subsequently withdrawn from the US market in 2013 due to hepatotoxicity (approximately 50 percent of patients developed clinically significant ALT elevation requiring monitoring or discontinuation). The compound is a non-selective reversible AChE and BChE inhibitor based on an aminoacridine scaffold. Mechanism includes additional weak NMDA receptor antagonism and modest sodium channel blockade, distinguishing the pharmacology from the more selective subsequent AChE inhibitors. The historical significance of tacrine is substantial; the compound established cholinesterase inhibition as a viable therapeutic strategy for Alzheimer disease and led to development of the more tolerable second-generation agents. The compound retains research utility as a pharmacological probe and AChE reference compound. Pharmacokinetics: short half-life (3 to 4 hours), four-times-daily dosing required in the marketed formulation. Hepatotoxicity is dose-related and reversible on discontinuation in most cases.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-048Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tirzepatide

Plain-language summaryIntrigue 93 / 100

Tirzepatide, sold as Mounjaro and Zepbound, is the first dual GLP-1 and GIP receptor agonist. By activating both incretin receptors, it produces more weight loss than semaglutide in head-to-head trials. Approved by the FDA in 2022. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel frontier

80/100

Dual incretins done right: the FDA-approved benchmark that defines what GIP/GLP-1 co-agonism can achieve

Look, tirzepatide isn’t just another incretin. The whole story starts at the receptor pharmacology: GIP and GLP-1 agonism together produce a genuinely additive effect that neither receptor achieves alone. GIP engagement modulates adipose tissue metabolism and potentiates insulin secretion in a glucose-dependent fashion; GLP-1 handles central satiety signaling, gastric emptying delay, and glucagon suppression. Running both pathways simultaneously turns out to be more than the sum of its parts, and the SURMOUNT program is the evidence base that confirmed it at scale.

SURMOUNT-1, published in the New England Journal of Medicine in 2022, showed average weight loss of 20.9% at the 15 mg weekly dose in adults with obesity over 72 weeks, with N above 2500. These arent modest numbers from a single lab. SURMOUNT-2, -3, and -4 extended the findings to T2DM populations, confirmed durability after withdrawal, and locked in the dose-response relationship. Multiple RCTs, multiple populations, consistent signal. The evidence quality here is genuinely high for a peptide compound.

What we find most interesting from a research standpoint is what the GIP component actually contributes. GLP-1 monotherapy was already well-validated before tirzepatide arrived. In a real sense, tirzepatide is the controlled experiment for what layering GIP receptor agonism adds on top of established GLP-1 biology. The GIP receptor’s role in adipose tissue, its interactions with adiponectin signaling, and the downstream effects on fat mass independent of energy intake are not fully characterized, and tirzepatide is one of the few available probes for studying that biology at clinically meaningful concentrations.

We dont think it’s breaking news anymore, though. Tirzepatide is FDA-approved, widely prescribed, and the research program is maturing fast. Novelty has a shelf life, and this compound is burning through it. Retatrutide is already in phase 2 with a triple agonist profile adding glucagon receptor activity, which makes tirzepatide look like a stepping stone in a rapidly evolving pharmacology story. Bench investigators focused purely on incretin frontier biology will want to be watching that space closely.

For investigators working on metabolic pharmacology, incretin receptor biology, adipose tissue signaling, or GLP-related satiety circuitry, tirzepatide remains one of the most useful tools available. The evidence base is unusually clean. The mechanism is well-defined. And the gap it opened between dual and single GLP-1 agonism is exactly the kind of differentiated signal that gives a research program somewhere real to go. The score reflects a compound that genuinely moved the field, even as the field is already starting to move past it.

Novelty

72

Mechanism promise

85

In-category differentiation

80

Evidence quality

87

Translational signal

88

Research bench value

68

Rationale Tirzepatide scores high on mechanism promise and evidence quality because the SURMOUNT trial program is unusually clean and large for a peptide this young, and the dual-receptor pharmacology is genuinely differentiated from GLP-1 monotherapy. Novelty is real but moderating now that it’s an approved, widely-prescribed agent; retatrutide’s emergence makes tirzepatide look increasingly like the floor of what’s possible in this class rather than the ceiling.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GIP/GLP-1 dual receptor agonist

A dual GIP and GLP-1 receptor agonist FDA-approved as Mounjaro (T2DM, 2022) and Zepbound (obesity, 2023), producing greater weight loss than GLP-1-only agents.

Abstract

Tirzepatide (Mounjaro, Zepbound; CAS 2023788-19-2; molecular weight 4813.54) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist developed by Eli Lilly and approved by the FDA for type 2 diabetes (2022) and chronic weight management (2023). The compound is a 39-amino-acid synthetic peptide based on the GIP scaffold with modifications at positions enabling GLP-1 receptor agonism alongside GIP receptor activity. Mechanism is dual GIP/GLP-1 receptor agonism producing complementary effects: GIP engagement adds to GLP-1’s glucose-dependent insulin secretion and contributes to weight regulation through fat metabolism modulation; GLP-1 contributes the central satiety, gastric emptying, and glucagon suppression effects. The combination produces substantially greater weight loss than GLP-1 monotherapy: SURMOUNT trials showed 15 to 22 percent weight loss over 72 weeks at 5 to 15 mg weekly doses. Approved doses titrate to 5, 10, or 15 mg per week subcutaneous.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-083Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Schisandra chinensis

Plain-language summaryIntrigue 48 / 100

Schisandra (Chinese magnolia vine) berry is an adaptogen used in traditional Chinese medicine for stress, fatigue, and liver support. The lignans class drives the activity. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

25/100

Well-characterized adaptogen lignan with diffuse mechanism and thin human evidence, outcompeted in every niche

Look, Schisandra chinensis has been in the Chinese pharmacopeia for centuries, and the bench literature has expanded correspondingly. But expanded doesn’t mean improved. The active constituents, the schizandrin lignans (schizandrin A, B, C, gomisin A, gomisin N, and a handful of others), are reasonably well characterized chemically, and theres a modestly sized body of work on hepatoprotection in rodent liver injury models. That’s the ceiling of the story, and it’s not a high ceiling.

The mechanism picture is diffuse to the point of frustration. Nrf2 pathway activation, antioxidant effects, HPA axis modulation, vague adaptogenic stress-tolerance framing: these are the kinds of multi-mechanism claims that look comprehensive on a monograph page but are hard to operationalize at the bench. The CYP3A induction activity is probably the most mechanistically specific angle, and that’s primarily relevant as a drug interaction liability, not a productive research target in itself.

The differentiation problem is real. Schisandra sits in a crowded adaptogen space alongside Rhodiola rosea, Withania somnifera, Eleutherococcus senticosus, and Panax ginseng. Each of those alternatives has at least one distinctive mechanistic claim or a more developed trial base. Rhodiola has the SHR-5 extract work and the partial MAO inhibition angle. Ashwagandha has the KSM-66 RCT series and a consistent cortisol signal. Schisandra’s hepatoprotective niche is real but contested by compounds with significantly better evidence: silymarin, TUDCA, NAC. On no single dimension does Schisandra clearly win.

On translational signal, the honest picture is thin. Human trials exist but are small, poorly blinded, and concentrated in Eastern European and Chinese research groups without independent replication. Effect sizes in stress-tolerance and endurance outcomes are modest and inconsistently reported across studies. We dont think the preclinical signal is fabricated; the schizandrins do interesting things in hepatocyte injury models. But the bench-to-clinic arrow is weak, and the question of whether those rodent outcomes generalize to meaningful human endpoints remains open in a way that’s not particularly exciting to work on right now.

For bench utility, Schisandra isn’t zero. If you’re running a lignan pharmacokinetics panel, building a CYP3A induction comparison, or designing a comparative adaptogen study that needs a reference compound, it has a slot. But thats a narrow role. A researcher designing a program around Schisandra specifically would struggle to justify that choice against the available alternatives, and we think most serious investigators already know that. The score reflects it.

Novelty

22

Mechanism promise

28

In-category differentiation

25

Evidence quality

28

Translational signal

25

Research bench value

22

Rationale Schisandra scores low on novelty (decades-old herb in a crowded adaptogen category) and differentiation (no clear superiority over Rhodiola, ashwagandha, or silymarin on any key metric); the schizandrin lignan profile is chemically interesting but translational evidence is thin and concentrated in single-consortium work without independent replication, placing the raw calculated score well below the OTC-herb cap.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Chinese magnolia vine berry adaptogen

A Chinese berry traditionally used as the ‘five flavors fruit’ for endurance, mental clarity, and hepatoprotection, characterized by schizandrins.

Abstract

Schisandra chinensis (Wu Wei Zi, “five flavors fruit”) is a climbing vine from China and Russia whose berries have been used for endurance, mental clarity, hepatoprotection, and longevity. The active constituents are lignans called schizandrins (schizandrin, gomisin A, gomisin N, and others). Modest hepatoprotective effects in liver injury models, antioxidant effects, and stress-tolerance effects have been documented. The schizandrins are CYP3A inducers, which has clinical drug interaction implications. Doses are typically 500 to 2000 mg per day of berry extract.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-115Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Liraglutide

Plain-language summaryIntrigue 80 / 100

Liraglutide, sold as Victoza and Saxenda, was the first daily GLP-1 receptor agonist approved for both diabetes (Victoza) and weight loss (Saxenda). It paved the way for the entire GLP-1 obesity drug class. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

The founding daily GLP-1 agonist, now eclipsed by semaglutide on nearly every metric that matters

Look, liraglutide earns its place in the library as the compound that first proved GLP-1 receptor agonism could sustain meaningful weight loss in a real clinical setting. The SCALE obesity program, the LEADER cardiovascular outcomes trial, FDA approvals for both T2DM and chronic weight management: the evidence base is legitimate and well-replicated. The problem is that “legitimate and well-replicated” now describes a 2010-era compound that’s been clearly outclassed in nearly every direction that matters to a bench investigator today.

The mechanism is GLP-1R agonism, single-target, well-understood. The palmitoyl fatty acid chain and albumin-binding strategy for extending half-life to roughly 13 hours was genuinely clever engineering at the time, enabling once-daily subcutaneous dosing when that was the frontier. But the same albumin-binding logic, applied to a longer chain and a refined backbone, gave Novo Nordisk semaglutide: weekly dosing, roughly double the weight-loss efficacy, a cardiovascular mortality signal, a renal protection signal, and eventually oral bioavailability. The engineering that made liraglutide work also showed researchers exactly how to do it better.

On differentiation, this is where liraglutide really struggles. It’s not competitive with semaglutide on efficacy. It’s not competitive with tirzepatide on mechanism breadth. Within the daily-dosing GLP-1 space it has no surviving advantage: dulaglutide is weekly, exenatide extended-release is weekly, semaglutide oral is approved. Daily dosing is a liability, not a feature. Cross-program comparisons between the SCALE and STEP trial families have formalized the hierarchy, with semaglutide delivering roughly 15-17% body weight reduction versus liraglutide’s ~8% in the SCALE trials.

What liraglutide retains is real research utility as a reference compound. If youre running a GLP-1R biology study, liraglutide is a well-characterized probe with known receptor-binding affinity constants, decades of pharmacokinetic data, and a predictable safety profile at research doses. It serves as a positive control in screens, and the LEADER cardiovascular data provides a concrete clinical comparator for any new compound trying to demonstrate CV benefit in the GLP-1 class. Thats genuine bench value, but it’s the bench value of an established reference tool, not an active investigation target.

We think liraglutide belongs in the library primarily as context: what the first generation of long-acting GLP-1R agonists looked like, and why the class evolved the way it did. For a researcher trying to understand GLP-1 biology deeply, it’s worth knowing. For a researcher trying to identify the next compelling metabolic target, it mostly points toward semaglutide, tirzepatide, or the triple agonists further along the development curve. Honest assessment: this is a workhorse that has already done its most important work.

Novelty

22

Mechanism promise

45

In-category differentiation

15

Evidence quality

78

Translational signal

70

Research bench value

55

Rationale Liraglutide defined the GLP-1 obesity category and carries genuinely strong evidence (SCALE program, LEADER CV outcomes trial), but single-target GLP-1R agonism at daily dosing is now a legacy profile; semaglutide’s superior efficacy and weekly schedule have made liraglutide a historical reference rather than a live research priority, and differentiation scores accordingly low.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Daily GLP-1 receptor agonist

A daily-dosing GLP-1 analog FDA-approved as Victoza (T2DM, 2010) and Saxenda (obesity, 2014); the predecessor of semaglutide.

Abstract

Liraglutide (Victoza, Saxenda; CAS 204656-20-2; molecular weight 3751.20) is a long-acting GLP-1 receptor agonist developed by Novo Nordisk and approved by the FDA for T2DM (2010) and obesity (2014). The compound features a 16-carbon fatty acid (palmitoyl) chain attached to lysine 26 via a glutamic acid spacer, enabling reversible albumin binding for extended half-life of approximately 13 hours, supporting once-daily subcutaneous dosing. Liraglutide was the first GLP-1 agonist approved for chronic weight management. Approved doses are 0.6 to 1.8 mg daily for T2DM and titrated to 3 mg daily for obesity.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-132Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Melatonin

Plain-language summaryIntrigue 65 / 100

Melatonin is the sleep hormone produced by the pineal gland in response to darkness. Supplementation is used for circadian rhythm disorders, jet lag, and sleep onset. The optimal dose is much lower than typically sold (0.3 mg, not 5-10 mg). Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

Canonical circadian probe with real evidence, but biologically settled and low on the novelty frontier

Look, melatonin is one of those compounds that scores well on evidence precisely because its research era is basically over. The MT1 and MT2 receptor pharmacology is fully mapped. The circadian phase-shifting literature goes back decades. Multiple well-designed RCTs confirm modest but real effects on sleep onset and jet lag. If you’re scoring “is there real data,” melatonin clears that bar handily. But that’s not what this rubric is asking.

The question is whether a serious bench scientist should be spending time here right now. And the honest answer for most investigators is no. The MT1/MT2 system is not an open frontier. The endogenous synthesis pathway from tryptophan through serotonin is textbook. The antioxidant angle gets mentioned in abstracts but the concentrations required for meaningful ROS scavenging in vivo are so far above physiological range that it doesn’t generate clean mechanistic insight. We’ve been down that road.

Where melatonin holds some residual bench value is as a reference ligand and timing tool for circadian entrainment experiments. If you’re studying chronobiology or trying to establish light-dark cycle baselines in rodent models, melatonin is what you reach for. Ramelteon is more selective at MT1/MT2, which makes it a sharper tool in some assay contexts, but melatonin’s endogenous status gives it ecological validity you dont get from a synthetic agonist. That’s a real but narrow argument for its continued utility.

The oncology literature is worth flagging as the one place where melatonin’s story isnt fully written. There’s a body of work, some of it multi-lab, pointing at adjunctive roles in solid tumor models, possibly through circadian disruption pathways. The Lissoni group’s clinical work from the 90s and 2000s is often cited but never quite confirmed at the scale or rigor you’d want. This is probably the most defensible reason a researcher might take a fresh look, but even here the signal hasn’t broken into mainstream oncology practice and the mechanism remains contested.

What we dont like: the gap between how widely this compound is discussed and how little genuinely open research territory remains. Most melatonin papers in 2025 are confirmatory or applied, not mechanistically generative. The pharmacokinetic variability at oral doses is real and relevant for study design, but it’s a methodological nuisance, not a scientific frontier. If your lab is doing circadian biology, keep a bottle on the shelf. If you’re looking for a research program, there are better places to build one.

Novelty

18

Mechanism promise

22

In-category differentiation

35

Evidence quality

62

Translational signal

58

Research bench value

52

Rationale Melatonin scores naturally low on novelty and mechanism because MT1/MT2 agonism and circadian phase-shifting are among the best-characterized pharmacology in all of chronobiology; evidence is actually solid by supplement standards, but the science is so settled it produces little frontier value for a bench investigator in 2026.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous indolamine hormone

An endogenous pineal hormone synthesized from serotonin, the master circadian regulator and a widely-used sleep supplement.

Abstract

Melatonin (N-acetyl-5-methoxytryptamine; CAS 73-31-4; molecular formula C13H16N2O2; molecular weight 232.28) is an endogenous indolamine synthesized in the pineal gland from serotonin via N-acetylation and 5-methoxylation. Endogenous melatonin secretion peaks during darkness and is the principal hormonal signal of biological night. Supplementation is widely used for sleep onset, jet lag, and shift work sleep. Mechanism is MT1 and MT2 melatonin receptor agonism; the compound also has direct antioxidant activity. Pharmacokinetics: plasma half-life 30 to 50 minutes; oral bioavailability variable (15 to 50 percent). Doses for sleep are 0.3 to 5 mg orally 30 to 60 minutes before bedtime; lower doses (0.3 to 1 mg) may be more physiologically appropriate but commercial supplements typically provide higher doses.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-149Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Theacrine

Plain-language summaryIntrigue 52 / 100

Theacrine is a methylxanthine alkaloid found in kucha tea. It produces stimulant effects similar to caffeine but with reportedly less tolerance development and longer duration. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

30/100

A caffeine analog with a modest tolerance story and industry-dominated evidence base

Look, theacrine is basically caffeine with two extra methyl groups and a slower absorption curve. That sentence contains almost everything you need to know about its research profile. The compound is 1,3,7,9-tetramethyluric acid, found naturally in kucha tea (Camellia kucha) and some yerba mate, and it became commercially interesting when Compound Solutions started selling it as TeaCrine around 2014. Since then it has accumulated a small but real published literature. The problem is that almost all of it traces back to the same small circle of labs with funding ties to the commercial product.

The mechanism story isnt wrong. Adenosine receptor antagonism is real pharmacology, and the structural difference from caffeine (the 7,9-methylation pattern) likely does produce the slower onset and the reportedly attenuated tolerance development that the TeaCrine marketing leans on. Kuhman et al. 2015 and Ziegenfuss et al. 2017 both showed some signal on subjective energy and mood. We dont dismiss those results. But “some signal on subjective energy in small industry-sponsored trials” is a long way from a research program worth prioritizing. Effect sizes are modest, the studies are underpowered, and independent replication outside the Compound Solutions orbit is thin.

The tolerance angle is actually the only thing that gives theacrine any differentiation over caffeine as a research object. The idea that the additional methylation changes receptor kinetics in a way that slows tolerance is interesting mechanistically. But if you want to study adenosine receptor tolerance, you already have caffeine, which has 50 years of literature and is the de facto probe for this receptor family. Theacrine doesnt let you answer a question you couldnt answer with caffeine; it mostly gives you a marginally different pharmacokinetic profile and a commercial incentive to publish positive results.

We think theacrine occupies a real but narrow niche: its useful for performance nutrition research where the specific question is “is there a methylxanthine with lower tolerance liability than caffeine” and you need a test compound. That is a legitimate question. Its just not a high-priority one for most bench programs. The translational signal in humans is real but modest, the evidence quality is constrained by industry capture, and the compound lacks the kind of novel mechanism or strong independent replication that would push it up the priority stack. Honestly, if you’re building a CNS stimulant research program, caffeine + a good tolerance protocol answers more questions with better-validated tools. Theacrine is worth knowing about; it isnt worth centering a program around.

Novelty

30

Mechanism promise

28

In-category differentiation

35

Evidence quality

30

Translational signal

35

Research bench value

20

Rationale Theacrine scores low primarily because its mechanism is effectively adenosine receptor antagonism with a slightly different methyl pattern, offering little probe value beyond what caffeine already provides. The tolerance-development differentiation story is real but mostly validated by Compound Solutions-funded studies with small N, which caps both evidence quality and translational confidence.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Methylxanthine / kucha tea alkaloid

A methylxanthine present in kucha tea (Camellia kucha) with caffeine-like CNS effects but reduced tolerance development.

Abstract

Theacrine (1,3,7,9-tetramethyluric acid; CAS 2309-49-1) is a methylxanthine alkaloid present in kucha tea (Camellia kucha) and yerba mate. The compound has structural similarity to caffeine but with two additional methyl groups that produce a distinct pharmacology. Theacrine acts as an adenosine receptor antagonist (similar mechanism to caffeine) but with slower onset (peak effect at 1.5 to 2 hours) and reportedly slower tolerance development. The compound is sold as TeaCrine (Compound Solutions) for performance and energy applications. Doses are typically 100 to 300 mg per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-164Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Boswellia serrata

Plain-language summaryIntrigue 55 / 100

Boswellia serrata is the source of frankincense gum resin. Boswellic acids inhibit 5-lipoxygenase and produce anti-inflammatory effects, particularly in osteoarthritis and inflammatory bowel disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

Mature Ayurvedic anti-inflammatory with real but unremarkable 5-LOX signal and modest clinical effect sizes

Cap applied Common OTC food/herb — max 35

Look, Boswellia serrata is the kind of compound that shows up in every supplement stack but rarely makes it into a serious investigator’s notebook. The tree resin has been used in Ayurvedic practice for centuries, and the active fractions, boswellic acids with acetyl-11-keto-beta-boswellic acid (AKBA) as the most pharmacologically characterized constituent, do have a real mechanism: selective 5-lipoxygenase inhibition that reduces leukotriene synthesis without the gastrointestinal liability of COX pathway blockade. That selectivity is honestly the most interesting thing about it, and it was genuinely exciting when first characterized in the early 2000s.

The clinical literature is real. There are multiple randomized trials in osteoarthritis, including the H15 extract trials and the Loxin (5-Loxin) program, plus a handful of IBD studies, and the signal holds up across labs better than you’d expect from an herbal compound. Effect sizes are modest: functional improvement in OA symptoms, some signal in Crohn’s and ulcerative colitis. It’s not anecdote. But it’s also not surprising anymore, and the field has largely moved on from treating 5-LOX inhibition as a particularly exciting new axis.

Here’s the issue for a 2025 research program. Pharmaceutical 5-LOX inhibitors like zileuton give you cleaner pharmacology if you actually need to probe the leukotriene pathway. The boswellic acid literature is heavily standardized-extract-centric, which makes mechanistic bench work messy. You’re working with a mixture, not a defined compound. AKBA can be isolated, and theres a subset of papers doing exactly that, but the tool-compound story is complicated by absorption issues (poor oral bioavailability of boswellic acids is well-documented) and the absence of well-validated cellular assays that cleanly attribute effects to 5-LOX vs. other targets AKBA has been proposed to hit, including cathepsin G and microsomal prostaglandin E synthase 1.

We dont think this is a bad compound. It’s clearly doing something useful in joint and gut inflammation models. But the novelty bar is gone, the mechanism is fully characterized, and the clinical signal, while real, isnt pushing any frontier. If youre looking for a productive anti-inflammatory research target in 2025, there are better entries where the mechanism is fresher and the translational picture is still being written. Boswellia earned its place in the historical literature; it just doesnt have much left to teach us at the bench right now.

Novelty

20

Mechanism promise

35

In-category differentiation

30

Evidence quality

55

Translational signal

52

Research bench value

28

Rationale Boswellic acids have a legitimate 5-LOX mechanism and replicated clinical signal in OA and IBD, but the compound is decades old, the mechanism is fully characterized, and better defined tool compounds exist for leukotriene pathway probing; the OTC herb cap binds at 35 over a calculated 36.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Frankincense gum resin / boswellic acids

An Indian frankincense resin containing boswellic acids with selective 5-lipoxygenase inhibition for inflammatory conditions.

Abstract

Boswellia serrata (Indian frankincense) is a tree resin used in Ayurvedic medicine for inflammatory conditions, particularly osteoarthritis and inflammatory bowel disease. Active constituents are boswellic acids (acetyl-11-keto-beta-boswellic acid, AKBA, being the most pharmacologically characterized). Mechanism is selective inhibition of 5-lipoxygenase (5-LOX), reducing leukotriene synthesis. Doses are typically 300 to 1200 mg of standardized extract (typically standardized to 65 to 75 percent boswellic acids or to specific AKBA content) per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-180Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 55 56 57 58 59 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.